Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 42 public companies in the "Diagnostic substances" industry, but how does it compare to its peers? We will compare Lucira Health to similar businesses based on the strength of its profitability, risk, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Earnings & Valuation
This table compares Lucira Health and its peers top-line revenue, earnings per share and valuation.
Get Lucira Health alerts:| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lucira Health | $93.06 million | -$64.83 million | -0.05 |
| Lucira Health Competitors | $466.17 million | $9.58 million | -52.37 |
Lucira Health's peers have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Lucira Health has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's peers have a beta of 1.38, indicating that their average share price is 38% more volatile than the S&P 500.
Profitability
This table compares Lucira Health and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| Lucira Health Competitors | -1,437.85% | -124.65% | -30.99% |
Institutional & Insider Ownership
57.0% of Lucira Health shares are held by institutional investors. Comparatively, 45.4% of shares of all "Diagnostic substances" companies are held by institutional investors. 30.4% of Lucira Health shares are held by insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Lucira Health and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| Lucira Health Competitors | 341 | 626 | 1235 | 19 | 2.42 |
As a group, "Diagnostic substances" companies have a potential upside of 37.76%. Given Lucira Health's peers higher probable upside, analysts plainly believe Lucira Health has less favorable growth aspects than its peers.
Summary
Lucira Health beats its peers on 6 of the 9 factors compared.
About Lucira Health
(Get Rating)
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.